This test is most useful if any of these apply to you.
If you've had a complete blood count, this number was probably reported with it. It is measured in whole blood, usually from the same purple-top tube used for the rest of the blood count.
MPV stands for mean platelet volume. It is a size measurement. It tells you whether your platelets are running large or small on average, and platelet size says something about how active those cells are. It does not give a clean verdict by itself. That gap matters before you read your own result.
Platelets are fragments budded off from giant parent cells called megakaryocytes in your bone marrow. Their size is mostly set when they are formed, before they reach your bloodstream.
Bigger platelets tend to be busier. A large platelet carries more packets of clotting chemicals and more sticky surface proteins, so it is often more ready to clump. The result is reported in femtoliters, a tiny unit of volume, but the exact number depends heavily on the analyzer and how quickly the sample was run.
The strongest human evidence ties larger platelets to worse outcomes in people who already have heart disease. A hospital study of more than 200,000 first admissions found that the largest platelets carried roughly half again the risk of dying from vascular causes and close to double the risk of dying from ischemic heart disease, a jump comparable to what smoking or obesity adds.
Most coronary studies point in the same direction. Pooling 52 studies and about 47,000 patients with coronary artery disease, larger platelets tracked with higher long-term death rates, and the link held in people after a stent or an acute coronary event. In one study of heart attack patients treated with emergency angioplasty, those with larger platelets died more often over the following months, roughly 12 out of 100 versus 5 out of 100. Among people with a prior stroke, larger platelets went with modestly higher stroke risk.
If you already carry a diagnosis of heart or vascular disease, a persistently high MPV is a reasonable nudge to be aggressive about the things that actually move outcomes: blood pressure, ApoB, blood sugar, and smoking. MPV is not itself a treatment target.
This is why MPV fails as a simple good-number, bad-number test. In a general-population study of more than 17,000 adults, those with the largest platelets had about a fifth lower risk of dying over eight years, driven mostly by fewer cancer and other non-vascular deaths. Yet within the small subgroup who already had cardiovascular disease, larger platelets went the other way, with roughly 70 percent higher death risk. Another cohort of over 31,000 people found lower MPV linked to less future heart disease, though the general-population evidence is not consistent: other large cohorts found risk of death, heart attack, and stroke similar across MPV groups, with the platelet count rather than its size carrying the signal.
Both can be true. MPV is not one risk factor pointing one way. It is a readout of platelet biology whose meaning depends on the body it is measured in. In someone with damaged, inflamed arteries, larger platelets can add to a more clot-prone state and predict harm. In the Moli-sani data, the smallest-platelet group had more cancer and other non-vascular deaths. That does not make low MPV a cancer test. It means context is the test.
The one place MPV earns its keep clinically is when your platelet count is low. Size helps explain why. If platelets are being destroyed in the bloodstream, the marrow compensates by pumping out fresh, large ones, so MPV runs high. If the marrow itself is failing, the platelets that remain tend to be normal or small.
For telling an immune destruction problem apart from a marrow production problem, MPV catches about 76 of 100 true cases and correctly clears about 79 of 100. That is useful context, not a diagnosis. Immature platelet fraction is a newer platelet test. It measures the youngest platelets more directly and can flag a recovering marrow before the platelet count itself climbs, but it needs specific analyzers.
Chronic low-grade inflammation tends to push platelet size up. This is the slow pattern seen with obesity, diabetes, and vascular disease. But an intense active flare can do the opposite. In active rheumatoid arthritis and certain acute inflammatory attacks, MPV often drops, then climbs back once the flare is treated, though this pattern is not seen in every study. A single low reading during a flare is telling you about that moment, not your baseline.
More than most lab values, MPV is easy to misread, and the biggest distortions have nothing to do with your health.
When the sample is handled well, your own MPV is fairly steady. Repeat measurements in the same person vary by only a few percent, and most people stay in the same size band over time, with a typical drift under one femtoliter. That stability is why a trend beats a snapshot.
Treat MPV as background information when you already have a complete blood count. A true change is more convincing when the sample handling and analyzer are similar. A one-off wobble from a slow-handled tube is not biology.
Never act on MPV alone. Read it beside your platelet count first. A low count with high MPV raises the question of platelet destruction. A low count with low or normal MPV points more toward a marrow production issue. A lone out-of-pattern MPV with a normal count and no symptoms is often a sample-timing problem.
If the value is genuinely and repeatedly off, put it in context rather than chasing the number. Pair it with hs-CRP. That test is a sensitive marker of body-wide inflammation. Kidney function, blood sugar, ApoB, and blood pressure usually tell you far more about risk than MPV does.
Evidence-backed interventions that affect your MPV level
MPV is best interpreted alongside these tests.
MPV is included in these pre-built panels.